Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8528060 | Clinical Therapeutics | 2018 | 21 Pages |
Abstract
The results in the elbasvir monotherapy study showed that 10 to 50 mg of elbasvir was associated with a rapid decline in HCV viral load; the results in the grazoprevir monotherapy study suggest that doses of 50 mg of grazoprevir and higher are on the maximum response plateau of the dose-response curve for GT1-infected participants. The results of these proof-of-concept studies provided preliminary data for the selection of the dosages of elbasvir and grazoprevir to test in Phase II and III clinical studies. ClinicalTrials.gov identifiers: NCT00998985 (Protocol 5172-004) and NCT01532973 (Protocol 8742-002).
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Wendy W. MD, Iain P. MD, DPhil, Patricia MS, Amelia BS, Inge De PharmD, Martine MS, Christina MS, Kristien PhD, Xiaobi PhD, Zifang PhD, Deborah MS, Robert B. PhD, Edward MS, John A. MD, PhD, Joan R. MD, Frank J. PhD, Valentin MD, Zhanna MD, PhD,